DOCSLIB.ORG

Do Intra-Articular Steroid Injections Affect Glycemic Control in Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Do Intra-Articular Steroid Injections Affect Glycemic Control in Patients Evidence-based answers from the Family Physicians Inquiries Network Erin Kallock, MD; Do intra-articular steroid Jon O. Neher, MD Valley Family Medicine Residency, Renton, Wash. injections aff ect glycemic control Leilani St. Anna, MLIS, AHIP University of Washington in patients with diabetes? Health Services Library, Seattle EVIDENCE-BASED ANSWER yes, but the clinical importance mendation [SOR]: B, small cohort studies). A is minimal. A single intra-articular Intra-articular steroid injections into the steroid injection into the knee produces shoulder may briefl y raise postprandial (but acute hyperglycemia for 2 or 3 days in pa- not mean) glucose levels with larger and re- tients with diabetes who otherwise have peated doses (SOR: C, extrapolated from het- good glucose control (strength of recom- erogenous and mixed cohort studies). A single steroid injection into the knee joint Evidence summary 1 week; investigators measured fructosamine causes acute Two prospective cohort studies evaluated the levels (a measure of intermediate-term hyperglycemia eff ect on glycemic control of a single gluco- glucose control) at baseline and again for 2 or 3 days corticoid injection into the knee of patients 2 weeks after injection. in patients with with controlled type 2 diabetes (glycosylated Th e injection produced hyperglycemia in diabetes who hemoglobin A1c Ͻ7.0%). Th e fi rst enrolled all participants, with peak blood glucose lev- otherwise have 9 patients with symptomatic osteoarthritis of els ranging from 251 to 430 mg/dL and time to good glucose the knee unresponsive to 3 months of nonste- peak glucose usually less than 6 hours. Fruc- control. roidal anti-infl ammatory drugs (NSAIDs).1 tosamine levels didn’t change signifi cantly. All received a 50-mg injection of methylpred- nisolone acetate after maximal aspiration of No change in glucose any joint fl uid. No changes were made to the after a single shoulder injection diabetes care regimen, including medication, Two studies evaluated the eff ect of a single diet, or exercise prescriptions. shoulder injection. One prospective cohort With self-monitoring 6 times a day dur- study included 18 patients with diabetes ing the week after the injection, 7 patients (type not specifi ed, mean A1c=7.6%).3 All showed an increase over baseline blood glu- had shoulder pain unresponsive to NSAIDs cose levels of more than 2 standard devia- for more than a month, had not changed tions; values typically rose above 300 mg/dL. diabetes medications within the preceding Peak blood sugar elevation occurred 5 to 84 2 weeks, and had not had steroid therapy hours after injection; the hyperglycemic ef- within the preceding 3 months. fect lasted for 2 or 3 days. All patients received a single injection In a second cohort study, 6 patients re- containing 35 mg methylprednisolone ac- ceived a knee injection of 1 mL Celestone etate into the anterior glenohumeral joint. Chronodose (3 mg betamethasone acetate Th ey monitored their blood glucose levels and 3 mg betamethasone sodium phos- 6 times a day for 1 week and had a fructos- phate, comparable in anti-infl ammatory amine level drawn before injection and and glucocorticoid potency to 32 mg methyl- 2 weeks afterward. Th e injection produced no prednisolone acetate).2 Patients moni- signifi cant change in mean blood glucose or tored their blood glucose 6 times a day for fructosamine levels. CONTINUED JFPONLINE.COM VOL 59, NO 12 | DECEMBER 2010 | THE JOURNAL OF FAMILY PRACTICE 709 But repeated shoulder injections day 1 and 252Ϯ87 mg/dL on day 7; PϽ.05 raise postprandial glucose for both comparisons). Mean fasting glucose In contrast, another prospective cohort study levels didn’t change, however. followed 11 patients (8 with diabetes) who re- ceived 3 injections of 3.75 mg cortivazol (com- parable to 50 mg methylprednisolone acetate) Recommendations at 3-day intervals into 1 shoulder joint.4 In- Th e American Academy of Orthopedic Sur- vestigators checked fasting and postprandial geons treatment guidelines for osteoarthritis glucose levels before the fi rst injection and on of the knee don’t discuss possible adverse ef- post-treatment days 1, 7, and 21. fects from steroid injections.5 Th e American Th e shoulder injections elevated post- Diabetes Association makes no recommen- prandial glucose levels (from 170Ϯ60 dations regarding steroid injections in pa- mg/dL at baseline to 258Ϯ100 mg/dL on tients with diabetes. JFP References 1. Habib GS, Bashir M, Jabbour A. Increased blood glucose levels at the shoulder joint on blood glucose levels in diabetic patients. following intra-articular injection of methylprednisolone acetate Clin Rheumatol. 2007;26:566-568. in patients with controlled diabetes and symptomatic osteoar- 4. Younes M, Neff ati F, Touzi M, et al. Systemic eff ects of epidural thritis of the knee. Ann Rheum Dis. 2008:67;1790-1791. and intra-articular glucocorticoid injections in diabetic and non- 2. Habib G, Safi a A. Th e eff ect of intra-articular injection of beta- diabetic patients. Joint Bone Spine. 2007;74:472-476. methasone acetate/betamethasone sodium phosphate on blood 5. American Academy of Orthopaedic Surgeons. Treatment glucose levels in controlled diabetic patients with symptomatic of osteoarthritis of the knee (non-arthoplasty). Available at: osteoarthritis of the knee. Clin Rheumatol. 2009:28;85-87. www.aaos.org/research/guidelines/OAKguideline.pdf. Accessed 3. Habib GS, Abu-Ahmad R. Lack of eff ect of corticosteroid injection July 2, 2009. OCTOBER 2010 • VOLUME 20, NUMBER 10 www.clinicianreviews.com This woman’s lesions started on her legs, then spread to her trunk. What is the underlying cause? see DermaDiagnosis, page 5 >> Excellllence rs off Yea A PEER-REVIEWED JOURNAL THE CLINICAL RESOURCE FOR NP AND PA PRACTICE CE/CME FROM THE NP EDITOR-IN-CHIEF Infl uenza The Family 2010-2011 Finishes the Dissertation s health technology A peer-reviewed journal dedicated to keeping and methodology advance, the need for continued learn- Aing and scholarly activities has driven many of us to pursue Nurse Practitioners and Physician Assistants up-to-date in clinical advanced degrees. Many are poised in various states of com- pletion, with as many reasons for being stalled in one stage as there are degree programs. practice and important trends in health care delivery. THE MANDATE DEBATE Recently, in a conversation with friends, we reminisced about © Courtesy of CDC our “all-but-dissertation” days. Laura M. Gunder, DHSc, MHE, PA-C How Can We Increase Clinicians’ Bonnie Dadig, EdD, PA-C While the pain of the process Flu Vaccination Rates? has fi nally become a mere wince Pretest probability, rapid fl u in recollection, the memory of testing, antiviral therapy, how much support we each re- vaccination—will these tools f the golden rule of medi- for Healthcare Epidemiology of see Family, page 2 >> help reduce last season’s cine is “First, do no harm,” America (SHEA), “despite Her- some experts in infectious culean efforts to increase it.” fl u-related hospitalization Clinician Reviews diseases think the major- Now, SHEA and other pro- and mortality rates? is endorsed by the hCME/CE article hInterviews with PA and Iity of clinicians are dropping the fessional medical organizations American Society ball—at least when it comes to think it may be time to take the of Endocrine PAs infl uenza vaccination. For years, gloves off (fi guratively, of course). the rate of vaccination against The organization recently pub- fl u among health care person- lished a position paper in Infec- IN THIS ISSUE NP thought leaders nel has been “unacceptably low,” tion Control and Hospital Epide- Your Turn . 1 in the words of Neil Fishman, in which it “endorses a see Infl uenza, page 32 miology ECG Challenge . 6 hIntriguing MD, President of the Society policy in which annual infl uenza vaccination is a condition of both Malpractice Chronicle . 7 initial and continued [health care Grand Rounds . .13 personnel] employment and/ Case Studies: Toxicology . .16 or professional privileges.” The recommendation applies to all Endocrine Consult . .21 self-assessment hMalpractice Chronicle health care providers (and other Radiology Review . .30 workers) in all settings, as well as students and volunteers. Infection in RA Patients . .38 quizzes see Mandate, page 24 >> Classifi eds . .45 NOW AVAILABLE hhh Clinician Reviews Digital Edition Digital Edition Advantages • Live Web and E-mail links • Browse the entire issue • Send articles to colleagues • Create an electronic library or share them on Facebook, • Link directly to the CME/CE test Twitter, and LinkedIn • Download a mobile version hhhLook for our new enhanced Web site in 2011 www.clinicianreviews.com 710 THE JOURNAL OF FAMILY PRACTICE | DECEMBER 2010 | VOL 59, NO 12.
Load more

Recommended publications
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Immediate Hypersensitivity Reactions Caused by Drug Excipients: a Literature Review Caballero ML, Quirce S
    REVIEWS Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Caballero ML, Quirce S Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain J Investig Allergol Clin Immunol 2020; Vol. 30(2): 86-100 doi: 10.18176/jiaci.0476 Abstract The European Medicines Agency defines excipients as the constituents of a pharmaceutical form apart from the active substance. Immediate hypersensitivity reactions (IHRs) caused by excipients contained in the formulation of medications have been described. However, there are no data on the prevalence of IHRs due to drug excipients. Clinical manifestations of allergy to excipients can range from skin disorders to life-threatening systemic reactions. The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. The cases reported were sorted alphabetically by type of medication and excipient in order to obtain a list of the excipients most frequently involved for each type of medication. Key words: Allergy. Drug immediate hypersensitivity reaction. Excipient. Pharmaceutical excipients. Resumen La Agencia Europea de Medicamentos define los excipientes como los componentes de una forma farmacéutica diferenciados del principio activo. Se han descrito reacciones de hipersensibilidad inmediata causadas por los excipientes contenidos en la formulación de medicamentos. Sin embargo, no hay datos sobre la prevalencia de dichas reacciones. Las manifestaciones clínicas de la alergia a los excipientes pueden ir desde trastornos de la piel hasta reacciones sistémicas que ponen en peligro la vida. El objetivo de este estudio fue realizar una revisión de la literatura sobre la alergia a los excipientes farmacéuticos y recopilar las reacciones inmediatas descritas con diferentes tipos de medicamento, debido solo a excipientes contenidos en sus formulaciones.
    [Show full text]
  • Ep 0173478 A1
    Patentamt JEuropaischesJ European Patent Office @ Publication number: 0173 478 ^ ^ Office europeen des brevets EUROPEAN PATENT APPLICATION Application number: 85305552.3 © 'nt. CI ": A 61 K 35/78, A 61 K 31 /57 Dateof filing: 05.08.85 (A61K35/78, 31 :57),(A61K31/57, 31 :23, 31 :20) @ Priority: 15.08.84 GB 8420771 @ Applicant: EFAMOL LIMITED, Efamol House Woodbridge Meadows, Guildford Surrey GU1 1BA (GB) @ Date of publication of application: 05.03.86 @ Bulletin 86/10 efamol House woodbridge meadows, Guildford Surrey GU1 1BA (GB) @ Representative : Caro, William Egerton et al, J. MILLER & @ Designated Contracting States: AT BE CH DE FR GB IT CO. Lincoln House 296-302 High Holborn, London LILUNLSE WC1V7JH(GB) @ Treatment of skin disorders. A topical composition for skin treatment contains an anti- inflammatory glucocorticoid in combination with an essential fatty acid (EFA) of the n-6 or n-3 series or equivalent poly- unsaturated fatty acid, as such or in the form of a physio- logically acceptable derivative convertible in the body thereto. FIELD OF INVENTION The invention relates to compositions of y-linolenic acid and related materials with anti-inflammatory glucocorticoids and to the treatment of inflammatory skin disorders with them. BACKGROUND AND EXPLANATION OF INVENTION Much interest has been shown in recent years in essential fatty acid metabolism, especially in its relation to prosta- glandin (PG) metabolism and in particular to the balance of 1-series and 2-series PGs in the body. The main dietary essential fatty acid (EFA) utilised in the fully healthy human body is linoleic acid, but the Δ6- desaturase that converts it to the next acid in the n-6 series, namely y-linoleic acid (GLA) is at a low level of activity in many conditions.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton Et Al
    US007544192B2 (12) United States Patent (10) Patent No.: US 7,544,192 B2 Eaton et al. (45) Date of Patent: Jun. 9, 2009 (54) SINUS DELIVERY OF SUSTAINED RELEASE 5,443,498 A 8, 1995 Fontaine THERAPEUTICS 5,512,055 A 4/1996 Domb et al. 5,664,567 A 9, 1997 Linder (75) Inventors: Donald J. Eaton, Woodside, CA (US); 5,693,065. A 12/1997 Rains, III Mary L. Moran, Woodside, CA (US); 5,792,100 A 8/1998 Shantha Rodney Brenneman, San Juan Capistrano, CA (US) (73) Assignee: Sinexus, Inc., Palo Alto, CA (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 992 days. WO WOO1/02024 1, 2001 (21) Appl. No.: 10/800,162 (22) Filed: Mar 12, 2004 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2005/OO437O6A1 Feb. 24, 2005 Hosemann, W. et al. (Mar. 2003, e-pub. Oct. 10, 2002). “Innovative s Frontal Sinus Stent Acting as a Local Drug-Releasing System.' Eur: Related U.S. Application Data Arch. Otorhinolarynolo. 260:131-134. (60) Provisional application No. 60/454,918, filed on Mar. (Continued) 14, 2003. Primary Examiner Kevin C Sirmons (51) Int. Cl Assistant Examiner Catherine NWitczak A. iM sI/00 (2006.01) (74) Attorney, Agent, or Firm Morrison & Foerster LLP (52) U.S. Cl. ........................ 604/506; 604/510; 604/514 (57) ABSTRACT (58) Field of Classification Search .............. 604/93.01, 604/891.1. 890.1, 57, 59-64, 510, 514,506; S lication file f 606/196 The invention provides biodegradable implants for treating ee application file for complete search history.
    [Show full text]
  • Steroid Use in Clinical Practice
    Steroid Use In Clinical Practice DR. TIN WIN AUNG Consultant Endocrinologist Department of Diabetes & Endocrinology North Okkalapa General & Teaching Hospital Outlines ◼ Overview of Steroids → What are steroids? →Steroidogenesis, Regulation, Physiological & Adverse Effects ◼ Steroids use in Clinical practice → Classification → Topical Steroids → Inhaled Corticosteroids → Systemic Corticosteroids → Prevention & Treatment of Complications of using CS What are steroids? ◼ Steroids (short for corticosteroids) are synthetic drugs that closely resemble cortisol, a hormone that your adrenal glands produce naturally. ◼ Corticosteroids are different from the male hormone-related steroid compounds that some athletes use. Corticosteroids ◼ Corticosteroids divided into: –Glucocorticoids –Mineralocorticoids Endogenous Steroidogenesis Regulation of Cortisol Secretion ◼ Three major mechanisms control ACTH release and the Cortisol secretion (1) Negative feedback mechanism →ACTH from anterior pituitary (2) Diurnal variation →Levels are the highest in the morning on waking and the lowest in the middle of evening. (3) Stress- physical (trauma, surgery, exercise) - psychological (pain, anxiety, apprehension) - physiological (nausea, fever and hypoglycemia) The Role of Cortisol in Regulation of HPA Axis 20 mg/day Plasma Cortisol -140- 700 nmol/l (Ref: range) Glucocorticoids Physiological Effects Carbohydrate metabolism ↑gluconeogenesis and conserve glucose for use during stress or starvation. Protein metabolism catabolic effect → negative nitrogen balance
    [Show full text]
  • Serious Neurological Events Complicating Epidural Injections Of
    RMD Open: first published as 10.1136/rmdopen-2016-000320 on 22 September 2016. Downloaded from Editorial Serious neurological events complicating epidural injections of glucocorticoid suspensions: evidence for a direct effect of some particulate steroids on red blood cells Jean-Denis Laredo,1 Elisabeth Laemmel,2 Eric Vicaut2 To cite: Laredo J-D, The Food and Drug Administration (FDA) into the vertebral artery has also been Laemmel E, Vicaut E. Serious has not approved any injectable glucocortic- demonstrated in an animal study.7 Occlusion neurological events complicating epidural oid product for epidural administration, but of distal intramedullary arteries by steroid injections of glucocorticoid epidural injection of glucocorticoids is com- particles via an unexpected intra-arterial suspensions: evidence for a monly used to manage radicular neck and injection has been incriminated as the mech- direct effect of some back pain.1 Severe and sometimes fatal anism leading to cord infarction in severe particulate steroids on red neurological events have occurred immedi- neurological deficit occurring after foraminal blood cells. RMD Open 8 2016;2:e000320. doi:10.1136/ ately after epidural injection of glucocorti- steroid injections at the cervical spine. It has rmdopen-2016-000320 coids. Indeed, 90 events were reported to the been suggested that the tendency of steroid FDA Adverse Event Reporting System particles to coalesce and the size of their 2 fi ▸ Prepublication history and (FAERS) between 1997 and 2014. nal aggregates, which differ among the dif- additional material for this In the December 10, 2015 issue of the New ferent types of particulate steroids, may influ- 2 paper is available online.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of Ro5459072 in Patients with Primary Sjögren’S Syndrome
    Official Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME NCT Number: NCT02701985 Document Dates: Protocol Version 3: 30-Oct-2016 PROTOCOL TITLE: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 2A STUDY TO ASSESS THE EFFICACY OF RO5459072 IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME PROTOCOL NUMBER: BP30037 VERSION: 3 EUDRACT NUMBER: 2015-004476-30 IND NUMBER: 128528 TEST PRODUCT: RO5459072 SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 28 January 2016 DATE AMENDED Version 2: 01 August 2016 Version 3: See electronic date stamp below FINAL PROTOCOL APPROVAL Approver's Name Title Date and Time (UTC) Translational Medicine Leader 30-Oct-2016 15:40:47 CONFIDENTIAL STATEMENT The information contained in this document, especially any unpublished data, is the property of F.Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. RO5459072— F. Hoffmann-La Roche Ltd Protocol BP30037 Version 3 PROTOCOL AMENDMENT, VERSION 3: RATIONALE Protocol BP30037 has been amended to incorporate the following changes to the protocol: Section 4.2.3: Implementation of changes to eligibility criteria . The eligibility criteria of the protocol have therefore been amended to mandate testing for tuberculosis and exclude patients with positive results.
    [Show full text]
  • Intraarticular Corticosteroid for Treatment of Osteoarthritis of the Knee (Review)
    Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review) Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2005, Issue 2 http://www.thecochranelibrary.com Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review) Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 RESULTS....................................... 3 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 15 ACKNOWLEDGEMENTS . 16 REFERENCES ..................................... 16 SOURCESOFSUPPORT . 21 INDEXTERMS .................................... 21 Intraarticular corticosteroid for treatment of osteoarthritis of the knee (Review) i Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Intraarticular corticosteroid for treatment of osteoarthritis of the knee N Bellamy, J Campbell, V Robinson, T Gee, R Bourne, G Wells Contact address: Nicholas Bellamy, Professor and Director, Medicine, Centre of National Research on Disability and Rehabilitation Medicine (CONROD), C Floor, Clinical Sciences Bldg., Royal Brisbane Hospital, Herston Road, Brisbane, Queensland
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Structures and Mechanism for the Design of Highly Potent Glucocorticoids
    Cell Research (2014) 24:713-726. © 2014 IBCB, SIBS, CAS All rights reserved 1001-0602/14 $ 32.00 npg ORIGINAL ARTICLE www.nature.com/cr Structures and mechanism for the design of highly potent glucocorticoids Yuanzheng He1, Wei Yi2, Kelly Suino-Powell1, X Edward Zhou1, W David Tolbert1, Xiaobo Tang2, Jing Yang3, Huaiyu Yang3, Jingjing Shi2, Li Hou2, Hualiang Jiang3, Karsten Melcher1, H Eric Xu1, 2 1Laboratory of Structural Sciences, Van Andel Research Institute, Grand Rapids, MI 49503, USA; 2VARI-SIMM Center, Center for Structure and Function of Drug Targets, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; 3Center for Drug Discovery and Design, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China The evolution of glucocorticoid drugs was driven by the demand of lowering the unwanted side effects, while keep- ing the beneficial anti-inflammatory effects. Potency is an important aspect of this evolution as many undesirable side effects are associated with use of high-dose glucocorticoids. The side effects can be minimized by highly potent gluco- corticoids that achieve the same treatment effects at lower doses. This demand propelled the continuous development of synthetic glucocorticoids with increased potencies, but the structural basis of their potencies is poorly understood. To determine the mechanisms underlying potency, we solved the X-ray structures of the glucocorticoid receptor (GR) ligand-binding domain (LBD) bound to its endogenous ligand, cortisol, which has relatively low potency, and a highly potent synthetic glucocorticoid, mometasone furoate (MF). The cortisol-bound GR LBD revealed that the flexibility of the C1-C2 single bond in the steroid A ring is primarily responsible for the low affinity of cortisol to GR.
    [Show full text]
  • Microsoft Word
    AUTORISES INTERDITS AC. ACETYLSALICYLIQUE AC. MEFENAMIQUE AC. CLAVULANIQUE AC. NALIDIXIQUE AC. FUSIDIQUE AC. PIPEMIDIQUE AC. NIFLUMIQUE AC. PIROMIDIQUE AC. OXOLINIQUE ACITRETINE AC. TIAPROFENIQUE ADRAFINIL AC. TIENILIQUE ALCOOL AC. TRANEXAMIQUE ALIZAPRIDE ACAMPROSATE ALLOPURINOL ACEBUTOLOL ALMINOPROFENE ACETAZOLAMIDE ALPRAZOLAM ACICLOVIR ALVERINE ACTH AMBROXOL ADRENALINE AMIDOPYRINE ALFENTANIL AMINEPTINE ALFUZOSINE AMINOGLUTHETIMIDE ALIMEMAZINE AMIODARONE AMANTADINE AMISULPRIDE AMFEPRAMONE AMOBARBITAL AMIKACINE ANDROGENES AMILORIDE ARTICAINE AMITRIPTYLINE ASTEMIZOLE AMLODIPINE BACLOFENE AMOXAPINE BARBITURIQUES AMOXICILLINE BENFLUOREX AMPHOTERICINE B BENZBROMARONE APTOCAINE BENZYL THIOURACILE ATENOLOL BEPRIDIL ATRACURIUM BETAHISTINE ATROPINE BIPERIDENE AZATHIOPRINE BISOPROLOL BENAZEPRIL BROMOCRIPTINE BENSERAZIDE BUPIVACAINE (*) BETA-ALANINE BUSPIRONE BETAXOLOL CAPTOPRIL BEZAFIBRATE CARBAMAZEPINE BLEOMYCINE CEFACLOR BROMAZEPAM CEFPODOXIME BROMURE CEFUROXIME BUFLOMEDIL CHLORAMPHENICOL BUPRENORPHINE CHLORMEZANONE BUTACAINE CHLOROQUINE (*) BUTYLHYOSCINE CIBENZOLINE CARBIMAZOLE CICLETANINE CARPIPRAMINE CIPROFIBRATE CEFIXIME CLINDAMYCINE CEFOTAXIME CLOBAZAM CEFTAZIDIME CLOFIBRATE CEFTRIAXONE CLOMETHIAZOLE CELIPROLOL CLOMIFENE CERIVASTATINE CLONIDINE CETIRIZINE CLORAZEPATE CHLORAL HYDRATE CLOTIAZEPAM CHLORDIAZEPOXIDE CYCLOPHOSPHAM 1 DE CHLORPROMAZINE CYPROTERONE CICLOSPORINE DANAZOL CILAZAPRIL DAPSONE CIMETIDINE DENORAL® CIPROFLOXACINE DEXFENFLURAMINE CISAPRIDE DEXTROMORAMIDE CITALOPRAM DEXTROPROPOXYPHENE CLARITHROMYCINE DIAZEPAM CLIDINIUM DIHYDRALAZINE
    [Show full text]